AIM ImmunoTech price target lowered to $1 from $2 at Maxim

Maxim analyst Jason McCarthy lowered the firm’s price target on AIM ImmunoTech (AIM) to $1 from $2 but keeps a Buy rating on the shares after meeting with its management to discuss the progress of Ampligen across its pipeline. The firm notes that the initial Imfinzi combo data from Phase 1b/2 DURIPANC study in metastatic pancreatic cancer shows a promising signal with stable disease in 2 out of 3 patients at 6 months, and though this is a small n- value, it is a highly challenging setting, the analyst tells investors in a research note. In long COVID, AIM has also identified moderate-to-severe fatigue as a target population based on the Amligen data from its Phase 2 in post-COVID fatigue, and the next step is to launch a follow-up study in this target setting, the firm added.